tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jeffrey Hung, 83 are a HOLD (30.07%), 17 are a SELL (6.16%), 176 are a BUY (63.77%).
Analyst Jeffrey Hung, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 59.43% that have a potential upside of 30.68% achieved within 171 days.
Jeffrey Hung’s has documented 531 price targets and ratings displayed on 41 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 08-Jan-2026.
Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 11/9/2022. The price target of $26 was fulfilled within 2 days with a profit of $3.75 (16.85%) receiving and performance score of 84.27.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 08-Dec-2021
$23
$-0.99 (-4.13%)
$22
18 days ago
(06-Feb-2026)
17/17 (100%)
$-0.56 (-2.38%)
84
Buy Since 26-Jun-2025
$31
$7.01 (29.22%)
$32
21 days ago
(03-Feb-2026)
0/5 (0%)
$6.24 (25.20%)
Buy Since 21-Oct-2025
$36
$12.01 (50.06%)
$33
1 months 18 days ago
(06-Jan-2026)
0/2 (0%)
$9.06 (33.63%)
Buy Since 17-Oct-2023
$40
$16.01 (66.74%)
$39
1 months 18 days ago
(06-Jan-2026)
2/7 (28.57%)
$13.06 (48.48%)
467
Hold Since 03-Nov-2022
$25
$1.01 (4.21%)
2 months 13 days ago
(11-Dec-2025)
18/21 (85.71%)
$-1.68 (-6.30%)
118
Which stock is Jeffrey Hung is most bullish on?
Which stock is Jeffrey Hung is most reserved on?
What Year was the first public recommendation made by Jeffrey Hung?
